ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.

Tightly regulated expression of the transcription factor PU.1 is crucial for normal hematopoiesis. PU.1 knockdown mice develop acute myeloid leukemia (AML), and PU.1 mutations have been observed in some populations of patients with AML. Here we found that conditional expression of promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA), the protein encoded by the t(15;17) translocation found in acute promyelocytic leukemia (APL), suppressed PU.1 expression, while treatment of APL cell lines and primary cells with all-trans retinoic acid (ATRA) restored PU.1 expression and induced neutrophil differentiation. ATRA-induced activation was mediated by a region in the PU.1 promoter to which CEBPB and OCT-1 binding were induced. Finally, conditional expression of PU.1 in human APL cells was sufficient to trigger neutrophil differentiation, whereas reduction of PU.1 by small interfering RNA (siRNA) blocked ATRA-induced neutrophil differentiation. This is the first report to show that PU.1 is suppressed in acute promyelocytic leukemia, and that ATRA restores PU.1 expression in cells harboring t(15;17).

[1]  W. Miller,et al.  CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. , 1999, The Journal of clinical investigation.

[2]  Jonathan D. Licht,et al.  Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .

[3]  R Berger,et al.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). , 1991, Blood.

[4]  D. Tenen,et al.  CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. , 2003, Blood.

[5]  J. Kutok,et al.  Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1 , 2004, Nature Genetics.

[6]  M. Klemsz,et al.  Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. , 1993, Blood.

[7]  A. Feeney,et al.  Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. , 1996, The EMBO journal.

[8]  M. Klemsz,et al.  The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene , 1990, Cell.

[9]  J. Licht,et al.  Transcription factors, normal myeloid development, and leukemia. , 1997, Blood.

[10]  D. Tenen,et al.  Inhibition of hematopoiesis by competitive binding of transcription factor PU.1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Tenen,et al.  PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. , 1996, Blood.

[12]  T. Graf,et al.  PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. , 1998, Genes & development.

[13]  C. Glass,et al.  Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. , 1995, Blood.

[14]  D. Tenen,et al.  Octamer Binding Factors and Their Coactivator Can Activate the Murine PU.1 (spi-1) Promoter* , 1996, The Journal of Biological Chemistry.

[15]  F. Pio,et al.  Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent. , 1998, Blood.

[16]  S. Minucci,et al.  Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.

[17]  M. Minden,et al.  Heterozygous PU.1 mutations are associated with acute myeloid leukemia. , 2002, Blood.

[18]  K. Kishi,et al.  Hematopoietic cytokine-dependent differentiation to eosinophils and neutrophils in a newly established acute promyelocytic leukemia cell line with t(15;17). , 1998, Experimental hematology.

[19]  W. Vainchenker,et al.  Spi-1/PU.1 transgenic mice develop multistep erythroleukemias , 1996, Molecular and cellular biology.

[20]  P. Silver,et al.  Retrovirus-delivered siRNA , 2002, BMC biotechnology.

[21]  P. Pelicci,et al.  Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. , 1998, Blood.

[22]  Donald Metcalf,et al.  Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors , 2005, The Journal of experimental medicine.

[23]  P. Kastner,et al.  Visualizing PU.1 activity during hematopoiesis. , 2005, Experimental hematology.

[24]  C. Preudhomme,et al.  Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? , 2002, Blood.

[25]  Najman,et al.  NB 4 , a Maturation Inducible Cell Line With t ( 15 ; 17 ) Marker Isolated From a Human Acute Promyelocytic Leukemia ( M 3 ) , 2022 .

[26]  A. Rowan,et al.  Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia , 2005, Oncogene.

[27]  B. Kistler,et al.  Lymphoid- and myeloid-specific activity of the PU.1 promoter is determined by the combinatorial action of octamer and ets transcription factors. , 1995, Oncogene.

[28]  Myriam Alcalay,et al.  The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells , 1993, Cell.

[29]  Daniel G Tenen,et al.  C/EBPβ: a major PML–RARA‐responsive gene in retinoic acid‐induced differentiation of APL cells , 2003, The EMBO journal.

[30]  S. Inoue,et al.  Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.

[31]  E. Scott,et al.  Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. , 1994, Science.

[32]  D. Tenen,et al.  PU.1 (Spi-1) autoregulates its expression in myeloid cells. , 1995, Oncogene.

[33]  D. Tenen,et al.  The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor , 1993, Molecular and cellular biology.

[34]  S. Nutt,et al.  Oncogenes and Tumor Suppressors (795 articles) Plenary Papers (356 articles) , 2004 .